Keros Therapeutics, Inc. (KROS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
26/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseKROS / S&P -3.08% / 15.20% |
LoseKROS / S&P -93.55% / 15.00% |
LoseKROS / S&P -1075.76% / 50.40% |
| 2026-Q11/3 |
LoseKROS / S&P -45.78% / -4.33% |
LoseKROS / S&P -84.55% / 11.30% |
WinKROS / S&P 1481.25% / 27.70% |
| 2025-Q42/3 |
WinKROS / S&P 28.70% / 2.65% |
WinKROS / S&P 6774.96% / 9.00% |
LoseKROS / S&P -146.09% / 13.40% |
| 2025-Q32/3 |
WinKROS / S&P 18.50% / 8.12% |
WinKROS / S&P 37798.31% / 4.61% |
LoseKROS / S&P -129.94% / 13.45% |
| 2025-Q22/3 |
WinKROS / S&P 31.01% / 10.94% |
WinKROS / S&P 85820.30% / 4.83% |
LoseKROS / S&P -106.43% / 10.63% |
| 2025-Q11/3 |
LoseKROS / S&P -35.63% / -4.27% |
WinKROS / S&P 91657.69% / 4.98% |
LoseKROS / S&P -96.89% / 10.57% |
| 2024-Q41/3 |
LoseKROS / S&P -72.74% / 2.41% |
WinKROS / S&P 2250.99% / 5.25% |
LoseKROS / S&P -4.04% / 6.15% |
| 2024-Q32/3 |
WinKROS / S&P 27.07% / 5.89% |
WinKROS / S&P 8037.50% / 5.89% |
LoseKROS / S&P 5.04% / 6.11% |
| 2024-Q21/3 |
LoseKROS / S&P -30.97% / 4.28% |
LoseKROS / S&P KROS unavailable / 5.38% |
WinKROS / S&P 12.75% / 5.12% |
| 2024-Q12/3 |
WinKROS / S&P 66.50% / 10.56% |
LoseKROS / S&P KROS unavailable / 5.71% |
WinKROS / S&P 16.78% / 5.59% |
| 2023-Q42/3 |
WinKROS / S&P 24.72% / 11.69% |
LoseKROS / S&P KROS unavailable / 6.81% |
WinKROS / S&P 25.00% / 7.78% |
| 2023-Q31/3 |
LoseKROS / S&P -20.66% / -3.27% |
LoseKROS / S&P KROS unavailable / 7.52% |
WinKROS / S&P 47.62% / -5.03% |
| 2023-Q21/3 |
LoseKROS / S&P -5.90% / 8.74% |
LoseKROS / S&P KROS unavailable / 9.50% |
WinKROS / S&P 37.46% / -8.57% |
| 2023-Q11/3 |
LoseKROS / S&P -11.08% / 7.50% |
LoseKROS / S&P KROS unavailable / 10.77% |
WinKROS / S&P 54.74% / -15.69% |
| 2022-Q42/3 |
WinKROS / S&P 27.64% / 7.56% |
LoseKROS / S&P KROS unavailable / 11.88% |
WinKROS / S&P 65.08% / -17.99% |
| 2022-Q32/3 |
WinKROS / S&P 36.16% / -4.88% |
LoseKROS / S&P KROS unavailable / 13.47% |
WinKROS / S&P 34.40% / -1.41% |
| 2022-Q21/3 |
LoseKROS / S&P -49.19% / -16.10% |
LoseKROS / S&P KROS unavailable / 13.71% |
WinKROS / S&P 48.43% / 11.04% |
| 2022-Q10/3 |
LoseKROS / S&P -7.06% / -4.60% |
LoseKROS / S&P KROS unavailable / 15.97% |
LoseKROS / S&P 30.73% / 42.23% |
| 2021-Q41/3 |
WinKROS / S&P 47.90% / 11.03% |
LoseKROS / S&P KROS unavailable / 15.00% |
LoseKROS / S&P KROS unavailable / 96.40% |
| 2021-Q30/3 |
LoseKROS / S&P -6.85% / 0.58% |
LoseKROS / S&P KROS unavailable / 10.77% |
LoseKROS / S&P KROS unavailable / 69.42% |
| 2021-Q20/3 |
LoseKROS / S&P -31.00% / 8.55% |
LoseKROS / S&P KROS unavailable / 6.58% |
LoseKROS / S&P KROS unavailable / 51.81% |
| 2021-Q10/3 |
LoseKROS / S&P -12.74% / 6.17% |
LoseKROS / S&P KROS unavailable / -1.06% |
LoseKROS / S&P KROS unavailable / 7.39% |
| 2020-Q41/3 |
WinKROS / S&P 82.89% / 12.15% |
LoseKROS / S&P -100.00% / -3.72% |
LoseKROS / S&P KROS unavailable / -33.42% |
| 2020-Q30/3 |
LoseKROS / S&P 2.83% / 8.93% |
LoseKROS / S&P KROS unavailable / -2.04% |
LoseKROS / S&P KROS unavailable / -27.10% |
| 2020-Q20/3 |
LoseKROS / S&P KROS unavailable / 20.54% |
LoseKROS / S&P KROS unavailable / -0.46% |
LoseKROS / S&P KROS unavailable / -27.11% |
| 2020-Q10/3 |
LoseKROS / S&P KROS unavailable / -19.60% |
LoseKROS / S&P KROS unavailable / 3.47% |
LoseKROS / S&P KROS unavailable / -14.75% |
| 2019-Q40/3 |
LoseKROS / S&P KROS unavailable / 9.07% |
LoseKROS / S&P KROS unavailable / 5.36% |
LoseKROS / S&P KROS unavailable / 2.99% |
| 2019-Q30/3 |
LoseKROS / S&P KROS unavailable / 1.70% |
LoseKROS / S&P KROS unavailable / 5.02% |
LoseKROS / S&P KROS unavailable / 0.21% |
| 2019-Q20/3 |
LoseKROS / S&P KROS unavailable / 4.30% |
LoseKROS / S&P KROS unavailable / 6.64% |
LoseKROS / S&P KROS unavailable / 8.65% |
| 2019-Q10/3 |
LoseKROS / S&P KROS unavailable / 13.65% |
LoseKROS / S&P KROS unavailable / 8.12% |
LoseKROS / S&P KROS unavailable / 14.29% |
| 2018-Q40/3 |
LoseKROS / S&P KROS unavailable / -13.52% |
LoseKROS / S&P KROS unavailable / 9.05% |
LoseKROS / S&P KROS unavailable / 18.23% |
| 2018-Q30/3 |
LoseKROS / S&P KROS unavailable / 7.71% |
LoseKROS / S&P KROS unavailable / 10.21% |
LoseKROS / S&P KROS unavailable / 19.06% |
| 2018-Q20/3 |
LoseKROS / S&P KROS unavailable / 3.43% |
LoseKROS / S&P KROS unavailable / 9.03% |
LoseKROS / S&P KROS unavailable / 14.46% |
| 2018-Q10/3 |
LoseKROS / S&P KROS unavailable / -0.76% |
LoseKROS / S&P KROS unavailable / 7.68% |
LoseKROS / S&P KROS unavailable / 12.46% |
| 2017-Q40/3 |
LoseKROS / S&P KROS unavailable / 6.64% |
LoseKROS / S&P KROS unavailable / 7.03% |
LoseKROS / S&P KROS unavailable / 13.82% |
| 2017-Q30/3 |
LoseKROS / S&P KROS unavailable / 4.48% |
LoseKROS / S&P KROS unavailable / 5.68% |
LoseKROS / S&P KROS unavailable / 17.57% |
| 2017-Q20/3 |
LoseKROS / S&P KROS unavailable / 3.09% |
LoseKROS / S&P KROS unavailable / 4.83% |
LoseKROS / S&P KROS unavailable / 17.74% |
| 2017-Q10/3 |
LoseKROS / S&P KROS unavailable / 6.07% |
LoseKROS / S&P KROS unavailable / 3.67% |
LoseKROS / S&P KROS unavailable / 13.32% |
| 2016-Q40/3 |
LoseKROS / S&P KROS unavailable / 3.82% |
LoseKROS / S&P KROS unavailable / 2.09% |
LoseKROS / S&P KROS unavailable / 7.05% |
| 2016-Q30/3 |
LoseKROS / S&P KROS unavailable / 3.85% |
LoseKROS / S&P KROS unavailable / 0.20% |
LoseKROS / S&P KROS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | KROS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -26.17% | 20.78% |
| Annualized return | -26.17% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | KROS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -66.75% | 83.14% |
| Annualized return | -19.76% | 12.86% |
10Y · 2020-04-08 to 2026-08-27
| Metric | KROS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -44.07% | 319.30% |
| Annualized return | -5.65% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |